US Bancorp
BHVN

US Bancorp’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

US Bancorp’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-306
Closed -$46K – 4370
2022
Q3 		$46K Sell
306
-568
-65% -$84.2K ﹤0.01% 2598
2022
Q2 		$127K Buy
874
+288
+49% +$36.8K ﹤0.01% 2111
2022
Q1 		$70K Buy
586
+94
+19% +$11.7K ﹤0.01% 2451
2021
Q4 		$68K Buy
492
+421
+593% +$53.5K ﹤0.01% 2486
2021
Q3 		$10K Buy
71
+62
+689% +$7.74K ﹤0.01% 3457
2021
Q2 		$1K Sell
9
-4
-31% -$325 ﹤0.01% 3981
2021
Q1 		$1K Sell
13
-271
-95% -$21.9K ﹤0.01% 3866
2020
Q4 		$25K Buy
+284
New +$24.1K ﹤0.01% 2830
2020
Q1 		– Sell
-10
Closed -$1K – 3944
2019
Q4 		$1K Hold
10
– – ﹤0.01% 3638
2019
Q3 		$0 Sell
10
-278
-97% -$11.7K ﹤0.01% 3791
2019
Q2 		$12K Buy
288
+234
+433% +$13.2K ﹤0.01% 3050
2019
Q1 		$3K Buy
+54
New +$2.33K ﹤0.01% 3397

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

US Bancorp's BHVN Position: Q4 2022 in Review

US Bancorp sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 306 shares — an estimated $46K sold.

US Bancorp first reported a position in BHVN in Q1 2019 and held it in 12 quarters. The position peaked at $127K in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • US Bancorp reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • US Bancorp sold 306 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $46K.
  • US Bancorp first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 12 quarters.
  • US Bancorp's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $127K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.